AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Continuous Glucose Monitoring versus Standard Self-Monitoring for Cardiovascular Risk Factors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
By Wadhwa P, Mohammed AH, SANDHU S et al.
Background: Cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus (T2DM).Continuous glucose monitoring (CGM) improves glycemic control, yet its impact on broader cardiovascular risk factors, including blood pressure and body weight, remains poorly characterized. We performed an updated systematic review and meta-analysis evaluating CGM versus self-monitoring of blood glucose (SMBG) on cardiovascular risk factors in adults with T2DM. Methods: PubMed, Cochrane CENTRAL, Embase, and Google Scholar were searched through May 2026. Eligible studies were randomized controlled trials (RCTs) comparing CGM to SMBG or usual care in adults with T2DM for ≥12 weeks, reporting cardiovascular risk factor outcomes. Random-effects meta-analyses were conducted using mean differences (MD) with 95%confidence intervals. Risk of bias was assessed using Cochrane RoB 2 for all includedstudies. Subgroup analyses by insulin treatment status and sensitivity analyses restricted to low-risk studies were pre-specified. PROSPERO: CRD420261410373. Results: Seventeen RCTs (n=2,252) were included. CGM significantly reduced HbA1c compared with SMBG or usual care (MD -0.42%, 95% CI -0.51 to -0.33; P<0.00001; I ² =11%) and significantly improved time in range (MD +11.35%, 95% CI 8.66 to 14.03; P<0.00001; I ² =0%;6 RCTs, n=1,052). HbA1c reductions were consistent across insulin-treated and non-insulin-treated subgroups (P for subgroup difference=0.81) and robust in sensitivity analyses restricted to low-risk studies (MD -0.41%, 95% CI -0.52 to -0.30; 13 RCTs). CGM did not significantly improve systolic blood pressure (MD +2.39 mmHg, 95% CI -2.03 to 6.82; P=0.29; 5 RCTs, n=521) or body weight (MD -0.67 kg, 95% CI -3.30 to 1.97; P=0.62; 8RCTs, n=890). Lipid profile data were available in only 2 studies, precluding pooled analysis; no significant between-group differences in LDL, HDL, or triglycerides were observed. Conclusions: CGM produces consistent, significant improvements in glycemic control and time in range in T2DM regardless of insulin treatment status. However, these glycemic benefits were not accompanied by significant improvements in blood pressure or body weight in currently available randomized trials. Long-term trials evaluating the impact of CGM on cardiovascularoutcomes in T2DM are needed.